

USSN: 10/647,561
Dkt. No.: 6800-0037.02
(SHE0037.14)
PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on:

11/27/06
Date


Loni M. Cummings

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

MICHAEL DAVID BENTLEY *et al.*

Confirmation No.: 3230

Application No.: 10/647,561

Art Unit: 1654

Filing Date: August 25, 2003

Examiner: Heard, Thomas Sweeney

Title: **POLYMER STABILIZED NEUROPEPTIDES**

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(c)**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sirs:

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98.

Pursuant to 37 C.F.R. §1.98, copies of publications A1-A7, B1-B3 and C1-C8 cited in the attached Form PTO/SB/08 are enclosed.

This Information Disclosure Statement is filed after the period specified in 37 C.F.R. § 1.97(b), but before the mailing of a final action under 37 C.F.R. § 1.113. In

accordance with 37 C.F.R. § 1.97(c) also enclosed is the fee under 37 C.F.R. § 1.17(p) in the amount of \$180.00.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.


It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Respectfully submitted,


Date:

November 17, 2006

By:


Susan T. Evans
Registration No. 38,443

ROBINS & PASTERNAK LLP
1731 Embarcadero Road, Suite 230
Palo Alto, CA 94303
Tel.: (650) 493-3400
Fax: (650) 493-3440

 <p>Substitute for form 449A/PTO</p> <p>PATENT INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>		Complete if Known			
		Application Number	10/647,561		
		Filing Date	August 25, 2003		
		First Named Inventor	BENTLEY, Michael D.		
		Group Art Unit	1654		
		Examiner Name	Thomas Sweeney Heart		
Sheet	1	of	1	Attorney Docket Number	6800-0037.02 (SHE0037.14)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A1	6,433,135		El-Tayar, et al.	08-13-2002
	A2	6,899,867		Bentley, et al.	05-31-2005
	A3	2002/0013266		Bentley, et al.	01-31-2002
	A4	2002/0019340		Bentley, et al.	02-14-2002
	A5	2003/0139346		Bentley, et al.	07-24-2003
	A6	2003/0144207		Bentley, et al.	07-31-2003
	A7	2004/0038899		Bentley, et al.	02-26-2004

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁵
		Office ³	Number ⁴	Kind Code			
	B1		WO98/52415		Fasano et al.	11/26/1998	
	B2		WO96/03984		Brem et al.	02/15/1996	
	B3		WO91/16355		Malfroy-Camine et al.	10/31/1991	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹	
	C1	Arap, <i>et al.</i> , "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model," <i>Science</i> <u>279</u> :377-380 (1998)		
	C2	Berendsen, "A Glimpse of the Holy Grail," <i>Science</i> <u>282</u> :642-643 (1998)		
	C3	Messer, "Vasopressin and Oxytocin," Web Document Updated 4-3-2000; http://www.neurosci.pharm.utoledo.edu/MBC3320/vasopressin.htm ; 5 pages		
	C4	Nagey, <i>et al.</i> , "Cytotoxic Analogs of Luteinizing Hormone-Containing Doxorubicin or 2-Pyrrolinodoxorubicin, A Derivative 500-1000 Times More Potent," <i>PNAS USA</i> <u>93</u> :7269-7273 (1996)		
	C5	Rudinger, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," JA Parsons, ed. pp. 1-7 (1976)		
	C6	Sigma, "Designing Custom Peptides," http://www.sigma-genosys.com/peptide_design.asp		
	C7	Smilek, <i>et al.</i> , "A Single Amino Acid Change in a Myelin Basic Protein Peptide Confers the Capacity to Prevent Rather than Induce Experimental Autoimmune Encephalomyelitis," <i>PNAS USA</i> <u>88</u> :9633-9637 (1991)		
	C8	Voet, <i>et al.</i> , "Abnormal Hemoglobins," Biochemistry, 2 nd ed., pp. 235-241 (1995)		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Applicant is to place a check mark here if English language Translation is attached.